Solid lipid nanoparticles of ondansetron HCl for intranasal delivery: development, optimization and evaluation

Area of Science:

• Pharmaceutical Technology
• Nanotechnology
• Drug Delivery

Background:

• Ondansetron HCl is used for managing nausea and vomiting.
• Intranasal delivery offers a direct route for nose-to-brain drug transport, bypassing the blood-brain barrier.
• Solid lipid nanoparticles (SLNs) are a viable drug delivery system for enhanced therapeutic efficacy.

Purpose of the Study:

• To develop and statistically optimize ondansetron HCl-loaded solid lipid nanoparticles (SLNs) for intranasal delivery.
• To evaluate the physicochemical characteristics, in vitro drug release, and in vivo brain targeting of the developed SLNs.
• To assess the safety of SLNs for nasal administration.

Main Methods:

• SLNs were prepared using the solvent diffusion technique.
• A 2(3) factorial design was employed for statistical optimization, varying lipid, surfactant, and cosurfactant concentrations.
• Particle size, entrapment efficiency, histological studies, TEM, DSC, XRD, in vitro release, and gamma scintigraphic imaging were performed.

Main Results:

• Optimized SLNs exhibited particle sizes ranging from 320-498 nm with entrapment efficiency between 32.89% and 56.56%.
• Histological examination showed no adverse effects on nasal mucosa.
• TEM confirmed spherical particle morphology, while DSC and XRD indicated complete drug encapsulation within the lipid matrix.
• In vitro release followed Fickian diffusion, and gamma scintigraphy demonstrated rapid brain localization in rabbits.

Conclusions:

• Statistically optimized ondansetron HCl SLNs are suitable for intranasal delivery.
• The developed SLNs facilitate rapid and direct nose-to-brain drug delivery.
• This formulation represents a promising strategy for treating neurological conditions via intranasal administration.